



Fc-fusion mimetics

Journal:	<i>Biomaterials Science</i>
Manuscript ID	BM-COM-02-2016-000077.R1
Article Type:	Communication
Date Submitted by the Author:	05-Apr-2016
Complete List of Authors:	Khalili, Hanieh; UCL School of Pharmacy, Pharmaceutics Khaw, Peng; UCL Institute of Ophthalmology Brocchini, Stephen; UCL School of Pharmacy, Pharmaceutics

Journal Name

COMMUNICATION

Fc-fusion mimetics

H. Khalili,^{a,b} P. T. Khaw,^b and S. Brocchini^{a,b}Received 00th January 20xx,
Accepted 00th January 20xx



DOI: 10.1039/x0xx00000x

www.rsc.org/

The Fc-fusion mimetic RpR **2** was prepared by disulfide bridging conjugation using PEG in the place of the Fc. RpR **2** displayed higher affinity for VEGF than aflibercept. This is caused primarily by a slower dissociation rate, which can prolong a drug at its site of action. RpRs have considerable potential for development as stable, organ specific therapeutics.

To achieve effective bivalency and high affinity, the two Fabs in an IgG antibody are mobile and are linked together as if each Fab (or protein) is bound at the end of linear molecule (Figure 1). FpFs **1** are IgG antibody mimetics (Figure 1) designed to have enhanced stability and binding properties compared to IgGs. They are prepared from PEG-di(mono-sulfone) **3** and two antibody fragments (Fabs).¹ Fc-based fusion proteins² (Figure 1) are also capable of

exploiting the therapeutic advantages of bivalency that are displayed by IgGs. Several Fc-fusion proteins are registered for clinical use³ and they will continue to offer considerable clinical potential because of Fc recycling, but they can be difficult to produce during early preclinical research and to scale for production.⁴ Fc-fusion proteins are also often prone to aggregation during downstream processing⁵ and have similar stability limitations as IgGs. There are therapeutic applications where the Fc is not needed or can cause problems.⁶ One area of interest is the use of antibody based medicines in organ specific applications such as the eye. In such cases, Fc recycling does not occur and effector function can be deleterious, especially in the treatment of inflammatory conditions. Improved stability is important to formulate more concentrated solutions to decrease the frequency of dose administration and improved binding properties such as slower dissociation rates are important for organ specific targeting.



^a UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK

^b NIHR Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, EC1V 9EL, UK

† Footnotes relating to the title and/or authors should appear here.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

COMMUNICATION

Journal Name

In an effort to further explore the potential of antibody-based mimetics that are made using the PEG-di(*mono*-sulfone) **3** (Scheme 1A, Figure 1) we describe an Fc-fusion mimetic that we call RpR **2**, for receptor binding region-PEG-receptor binding region.

Aflibercept (Eylea) is a Fc-fusion protein that is used to treat age related macular degeneration (AMD) by binding to vascular endothelial growth factor (VEGF) in the back of the eye. It is administered by intravitreal injection directly into the eye. Fc-fusion proteins are related to IgG antibodies in that both have an Fc domain. IgG antibodies have two heavy and two light chains. The Fc-domain comprises the C2 and C3 regions of the two heavy chains. Disulfide bonds exist in IgG antibodies that are between the heavy chains in the hinge region to separate the Fc domain from the hinge and Fabs. Aflibercept is a homodimer that comprises 2 monomers of (VEGFR₁-VEGFR₂)-(C2-C3), referred to here as VEGFR₁-VEGFR₂-Fc **5** (Scheme 1B), with disulfide bonds expected to be in the peptide sequence between the target binding domains (VEGFR₁-VEGFR₂) and the Fc domain (C2-C3 regions) (Figure 1).⁷ Aflibercept is glycosylated with a total molecular weight of 115 kDa, of which 97 kDa is due to the protein component. Each mono-sulfone moiety in reagent **3** undergoes site-specific conjugation with the two cysteine thiols from a disulfide bond by a sequence of addition-elimination reactions to insert a stable 3-carbon methylene bridge between the two thiols of the original disulfide bond (Scheme S1, ESI).⁸ The thiol ether bonds in a rebridged disulfide bond are more stable than the original disulfide bond. To make the desired RpR **2** we first had to obtain the VEGFR₁-VEGFR₂ fragment **4** by proteolytic digestion of aflibercept to remove the Fc domain (Scheme 1B).

It was first confirmed that aflibercept migrated to an approximate molecular weight of about 115 kDa by SDS PAGE (Figure 2, lane 1). Aflibercept was then treated with dithiothreitol (DTT) to reduce the accessible disulfide bonds thought to exist in an hinge like region between the binding domain (VEGFR₁-VEGFR₂) and the Fc domain. A broad band appeared at ~55-60 kDa by SDS-PAGE (Figure 2, lane 2). We believe this band corresponds to the monomeric VEGFR₁-VEGFR₂-Fc **5** (Scheme 1B). Glycosylation is usually somewhat heterogeneous in therapeutic proteins, so we inferred that the broadness of the band at ~55-60 kDa was due to glycosylation heterogeneity. DTT was then removed using a PD-10 column and the reduced aflibercept solution was incubated with Ellman's reagent which indicated the presence of 4 accessible cysteine thiols in aflibercept (Figure 1S, Table 1S, ESI). This suggested that there are 2 cysteines in each VEGFR₁-VEGFR₂-Fc **5** monomer which can form two disulfide bonds in aflibercept analogous to what is found in the hinge region of IgG antibodies. Hence it was thought possible that an RpR **2** derived from aflibercept could be prepared using the PEG-di(*mono*-sulfone) **3**. If only one cysteine had been present in the VEGFR₁-VEGFR₂-Fc **5** monomer, there are stable, mono-thiol conjugation linkers available⁹ that would have been utilised in a bifunctional reagent analogous to PEG-di(*mono*-sulfone) **3**.

Proteolytic digestion of aflibercept was then examined in an effort to obtain the monomeric VEGFR₁-VEGFR₂ fragment **4** (Figure 3). Preliminary digestion studies of aflibercept using immobilised papain yielded only difficult to characterise small peptide fragments. We had previously used papain to digest IgGs to obtain




Figure 2. SDS-PAGE gels of VEGFR₁-VEGFR₂ dimer **6** obtained by the proteolytic digestion of aflibercept and preparation of RpR **2**. Novex Bis-Tris 4-12% gel stained with colloidal blue for protein and barium iodide for PEG (lane 7). *M*: standard protein markers, *Lane 1*: aflibercept, *Lane 2*: aflibercept treated with DTT to give VEGFR₁-VEGFR₂-Fc monomer **5**, *Lane 3*: aflibercept-IdeS digestion mixture, *Lane 4*: VEGFR₁-VEGFR₂ dimer **6**, *Lane 5*: VEGFR₁-VEGFR₂ monomer **4**, *Lanes 6, 7*: purified RpR **2**.

Fabs,^{1, 10} but recognised that proteolytic digestion of different antibody subclasses and motifs can be difficult to control.¹¹

A second proteolytic enzyme (IdeS enzyme, FabRICATOR[®], Genovis) that can cleave an IgG at glycine-glycine bonds¹² in the hinge reagent to give F(ab)₂ was then examined. Incubation of aflibercept with IdeS resulted in 3 bands by SDS-PAGE (Figure 2, lane 3). New bands appeared at approximately 30 kDa and 60-70 kDa. A third band at approximately 95-100 kDa in this gel was thought to be undigested aflibercept. The lower molecular weight fragment at 30 kDa, which is thought to be the cleaved Fc, and the band for undigested aflibercept were removed by eluting the digestion mixture over a column that binds to the Fc domain (CaptureSelect Midispin, Genovis). This provided a purified a non-Fc containing fragment at 60-70 kDa (Figure 2, lane 4) which was thought to be the VEGFR₁-VEGFR₂ dimer **6** (Scheme 1B).

Incubation of VEGFR₁-VEGFR₂ dimer **6** with DTT caused this fragment to disappear to give 2 lower molecular weight fragments (Figure 2, lane 5). These fragments are thought to be the desired VEGFR₁-VEGFR₂ monomer **4** (Scheme 1). Two bands are often observed after reduction of Fabs that are obtained by proteolytic digestion. This can be due to miscleavage reactions during proteolysis and may be exacerbated for aflibercept due to its difference in structure compared to an IgG and due to aflibercept glycosylation. There are five N-glycosylation sites on each monomeric VEGFR₁-VEGFR₂-Fc fragment **5** which may be partially or completely glycosylated. There may also be additional heterogeneity caused by differences in saccharide structure.

To prepare the RpR **2**, the VEGFR₁-VEGFR₂ dimer **6** was first incubated with DTT for 30 minutes to give the VEGFR₁-VEGFR₂ monomer **4** (Scheme 1B). The reaction mixture was carefully eluted over a PD-10 column to remove the DTT while avoiding disulfide reformation, and then the PEG di(mono-sulfone) reagent **3** (derived from a 10 kDa PEG precursor) was added to the solution of the monomeric VEGFR₁-VEGFR₂ **4**. Incubation of the reaction mixture for 3 h (Figure 2S, lane 1, ESI) was then followed by purification by size exclusion chromatography (Figure 2S, lanes 2-10, ESI) to give the purified RpR **2** which appeared in a band at approximately 70 kDa (Figure 2, lanes 6 and 7). Two detection dyes were used, first coomassie blue to detect protein (lane 6) and then barium iodide to detect the PEG (lane 7) being conjugated to the protein. Starting from 0.8 mg (in 1.0 mL) of VEGFR₁-VEGFR₂ dimer **6**, approximately 0.16 mg (in 0.5 mL) of RpR **2** was obtained (~ 20 % yield).

At 25 °C the purified RpR **2** displayed a solution size of 10.7 ± 0.5 nm (Pd, 0.7 ± 0.1 nm), which is similar to the starting aflibercept (10.2 ± 0.7 nm; Pd, 0.6 ± 0.1 nm). The FpF antibody mimetics **1** were also a similar solution size to the corresponding IgG.¹ This is in stark contrast to when PEG is conjugated only at one terminus to a single protein where the solution size of a PEG-protein conjugate is dominated by the random coil nature of PEG.¹³ When only one terminus of PEG is conjugated to a protein, the other PEG terminus has considerable freedom to allow the PEG to maintain a large solution structure.

As a macromolecule, the RpR has a protein at each terminus of the PEG scaffold, which is analogous to an A-B-A block copolymer where it is known that the two functionalised end blocks can self-associate.¹⁴ The dimeric VEGFR₁-VEGFR₂ fragment **6** also displayed a solution size of 10.03 ± 0.1 nm (Pd, 0.7 ± 0.1 nm) which is similar to both aflibercept and RpR **2**. Interestingly, when the VEGFR₁-VEGFR₂ fragment **6** was treated with DTT and the cysteine thiols were blocked with iodoacetamide, the cysteine thiol-capped monomeric VEGFR₁-VEGFR₂ fragment **7** (Scheme 1B) displayed a solution size of 7.2 ± 0.4 nm (Pd, 0.7 ± 0.1 nm). Although the dimer **6** is twice the molecular weight of the VEGFR₁-VEGFR₂ monomer **7**, its size in solution is only about 40% larger suggesting that there may be some non-covalent intramolecular association between each of the VEGFR₁-VEGFR₂ monomers in the dimer **6**.

The binding properties of the RpR **2** and aflibercept were then evaluated by surface plasmon resonance (Biacore) to determine the affinity (K_D), and the rate constants of association (k_a) and dissociation (k_d) (Table 1). Vascular endothelial growth factor-165 (VEGF₁₆₅), which is a ligand for aflibercept, was immobilised at a density to minimise or prevent rebinding events (91 RU).^{1, 15} The dissociation rate (k_d) for the RpR **2** was slower than what was observed with aflibercept. Interestingly, the k_a appeared to be slightly faster in RpR **2** compared to aflibercept. This is in contrast to what was previously observed for anti-VEGF FpF which had a slower association rate than the precursor IgG antibody.¹ However it was the decreased k_d of RpR **2** that appeared to be the

dominating factor to cause the improved affinity of RpR **2** compared to aflibercept (Table 1). Representative fitting curves for aflibercept and RpR **2** are shown in the ESI (Figure S3, ESI).

Exploiting reduced dissociation rates may be a viable strategy to increase efficacy by increasing the residence time and mode of action within specific tissue.¹⁶ Although the reduction in k_d for FpF **1** is also slower than the parent IgG,¹ there appears to be a greater relative reduction in k_d for the RpR **2** compared to its parent Fc-fusion (i.e. aflibercept). During initial dissociation steps from the ligand of one of the two VEGFR₁-VEGFR₂ domains in the RpR **2**, PEG conformational flexibility may be more efficient for rebinding than the polypeptide linking the Fc domain to the VEGFR₁-VEGFR₂ domain in aflibercept. This suggests there is less flexibility in the bivalent binding moieties in the Fc-fusion protein (aflibercept) than there is in an IgG (e.g. bevacizumab).

The VEGF binding of the capped VEGFR₁-VEGFR₂ monomer **7** (Figure S4, ESI) was reduced when compared to the VEGFR₁-VEGFR₂ dimer **6**. This exemplified the advantages of the cooperative bivalent binding that is possible with (i) aflibercept, (ii) the dimeric VEGFR₁-VEGFR₂ fragment **6** and (iii) RpR **2** (Table 1). The similar binding properties that were observed for both the dimer **6** and aflibercept suggests that the placement of the accessible disulfide bonds linking each monomer in aflibercept is important for the mobility of the VEGFR₁-VEGFR₂ binding domains. Inclusion of a polypeptide sequence to extend the VEGFR₁-VEGFR₂ receptor domains away from the aflibercept disulfide bonds to better optimise dissociation rates would be expected to make aflibercept less stable. Such an added polypeptide sequence to increase the flexibility of the VEGFR₁-VEGFR₂ receptor domains would invariably lack secondary structure in a similar way to the hinge region of IgG antibodies. While the hinge region in IgG antibodies provides the flexibility needed for cooperative and bivalent binding of both Fabs,¹⁷ the IgG hinge region is also vulnerable to degradation and disulfide scrambling.¹⁸ The stable conjugation imparted by PEG-di(mono-sulfone) **3** and use of a PEG scaffold provides enough flexibility of the VEGFR₁-VEGFR₂ binding moieties to potentially maximise both association and dissociation rates that could be important in the development of new therapeutics.

Sample	k_a ($\times 10^5$) $M^{-1}s^{-1}$	k_d ($\times 10^{-4}$) s^{-1}	K_D (k_d/k_a) nM
Aflibercept	0.88	4.20	4.78
(VEGFR ₁ -VEGFR ₂) ₂ 6	1.20	5.20	4.30
RpR 2	1.13	1.90	1.71

Table 1. Binding kinetic constant rate of aflibercept, VEGFR₁-VEGFR₂ dimer **6** and RpR **2**, Affinity, dissociation and association rate constants were studied using CM3 chip immobilised with 91 RU human VEGF at 25 °C. The range of concentrations used for the conjugates was 0.06 μM to 1.6 μM. Data were collected from 2 independent experiments for RpR **2** and 3 independent experiments for aflibercept and VEGFR₁-VEGFR₂ dimer **6**.

RpR **2** was then evaluated *in vitro* using a human umbilical vein endothelial cell (HUVEC) co-culture (Figure 3). This assay measures the migration and the formation of an anastomosing network that is characterised by tubule and junction formation during HUVEC proliferation. These processes are characteristic for angiogenesis and are often a good *in vitro* measurement for angiogenesis.¹⁹ RpR **2** and aflibercept were incubated with VEGF₁₆₅ at different molar ratios of 3.0, 1.5, 0.5 for 2 hours at 37°C prior to incubation with HUVECs. VEGF₁₆₅ and anti-mouse TNF-α IgG were used for positive controls. Images were obtained after fixing HUVECs with an anti-CD31 antibody to differentiate between the endothelial tubular network and non-endothelial structures of similar apparent morphology (Figure 3A). These images suggest that both aflibercept and RpR **2** have similar anti-angiogenic properties. Quantification of tubule (Figure S5, ESI) and junction formation (Figure 3B) (AngioSys Image Analysis Software, TCS Cellworks Ltd.) showed that the formation of these structures were similarly inhibited in a concentration dependent manner by both RpR **2** and aflibercept.


To summarise, a new antibody Fc-fusion mimetic called an RpR was prepared. Aflibercept is a clinically used Fc-fusion protein that targets VEGF was used for these studies. Proteolytic digestion of aflibercept followed by incubation with DTT provided the monomeric VEGFR₁-VEGFR₂ domain **4** that was then conjugated to the PEG-di(mono-sulfone) **3** by disulfide bridging conjugation to

give the anti-VEGF RpR **2**. The strategy to proteolytically digest aflibercept provided the means to compare the properties of the RpR Fc-fusion mimetic **2** with aflibercept. The solution size of RpR **2** and its *in vitro* activity are comparable to aflibercept. Of most interest is that binding studies show that RpR **2** has higher affinity for VEGF compared to aflibercept primarily due to a slower dissociation rate. Antibody based mimetics such as RpR **2** have potential for development as stable, organ specific therapeutics.

We are thankful for funding from the National Institute of Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, Moorfields Special Trustees, the Helen Hamlyn Trust (in memory of Paul Hamlyn), Medical Research Council, Fight for Sight and Freemasons Grand Charity. SB is also grateful for funding from the UK Engineering & Physical Sciences Research Council (EPSRC) for the EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies. Financial support from the consortium of industrial and governmental users for the EPSRC Centre is also acknowledged.

Notes and references

1. H. Khalili, A. Godwin, J. W. Choi, R. Lever, P. T. Khaw, and S. Brocchini, *Bioconjugate Chem.*, 2013, **24**, 1870-1882.
2. (a) S. M. Chamow, T. Ryll, H. B. Lowman, and D. Farson, eds. *Therapeutic Fc-Fusion Proteins*. Vol. 10. 2013, Wiley Blackwell: Weinheim. 419; (b) D. M. Czajkowsky, J. Hu, Z. Shao, and R. J. Pleass, *EMBO Mol. Med.*, 2012, **4**, 1015-1028.
3. W. R. Strohl, *BioDrugs* 2015, **29**, 215-239.
4. (a) A. B. V. Spriel, H. H. V. Ojik, and J. G. J. Winkel, *Immunol. Today* 2000, **21**, 391-398; (b) H. R. Hoogenboom, *Nat. Biotechnol.*, 1997, **15**, 125-126.
5. (a) A. A. Cordes, C. W. Platt, J. F. Carpenter, and T. W. Randolph, *J. Pharm. Sci.*, 2012, **101**, 1400-1409; (b) M. C. Manning, D. K. Chou, B. M. Murphy, R. W. Payne, and D. S. Katayama, *Pharm. Res.*, 2010, **27**, 544-575.
6. (a) M. Kolfschoten, J. Schuurman, M. Losen, W. K. Bleeker, P. Martinez, E. Vermeulen, T. H. D. Bleker, D. Wiegman, T. Vink, L. A. Aarden, M. H. D. Baets, J. Winkel, R. C. Aalberse, and P. Parren, *Science* 2007, **13**, 1554-1557; (b) S. Murinello, R. F. Mullins, A. J. Lotery, V. H. Perry, and J. L. Teeling, *Invest. Ophthalmol. Vis. Sci.*, 2014, **55**, 247-258; (c) A. L. Nelson, *MABs*, 2010, **2**, 77-83; (d) A. Chapman, P. Antoniw, M. Spitali, S. West, S. Stephens, and D. King, *Nat. Biotechnol.*, 1999, **17**, 780-783.
7. (a) EMA (European Medicines Agency), *Assessment report for aflibercept (EMA/646256/2012)*, European Medicines Agency Committee for Medicinal Products for Human Use, Editor. 2012. p. 83; (b) K. K. Ciombor, J. Berlin, and E. Chan, *Clin. Cancer. Res.*, 2013, **19**, 1920-1925; (c) J. Holash, S. Davis, N. Papadopoulos, S. D. Croll, L. Ho, M. Russell, P. Boland, R. Leidich, D. Hylton, E. Burova, E. Ioffe, T. Huang, C. Radziejewski, K. Bailey, J. P. Fandl, T. Daly, S. J. Wiegand, G. D. Yancopoulos, and J. S. Rudge, *Proc. Natl. Acad. Sci. U S A*, 2002, **99**, 11393-11398.



8. (a) S. Shaunak, A. Godwin, J. W. Choi, S. Balan, E. Pedone, D. Vijayarangam, S. Heidelberger, I. Teo, M. Zloh, and S. Brocchini, *Nat. Chem. Biol.*, 2006, **2**, 312-313; (b) S. Balan, J. W. Choi, A. Godwin, I. Teo, C. M. Laborde, S. Heidelberger, M. Zloh, S. Shaunak, and S. Brocchini, *Bioconjugate Chem.*, 2007, **18**, 61-76.
9. G. Badescu, P. Bryant, J. Swierkosz, F. Khayrzad, E. Pawlisz, M. Farys, Y. Cong, M. Muroi, N. Rumpf, S. Brocchini, and A. Godwin, *Bioconjugate Chem.*, 2014, **25**, 460-469.
10. H. Khalili, A. Godwin, J. Choi, R. Lever, and S. Brocchini, *Bioconjugate Chem.*, 2012, **23**, 2262-2277.
11. (a) M. G. Mage, *Methods Enzymol.*, 1980, **70**, 142-150; (b) P. Parham, *J. Immunol.*, 1983, **131**, 2895-2902.
12. (a) B. P. Johansson, O. Shannon, and L. Bjorck, *PLoS One*, 2008, **3**, 1-6; (b) P. Åkesson, L. Moritz, M. Truedsson, B. Christensson, and U. V. Pawel-Rammingen, *Infection and Immunity* 2006, **74**, 497-503.
13. C. Fee, *Biotechnol. Bioeng.*, 2007, **98**, 725-731.
14. (a) F. Lo Verso and C. N. Likos, *Polymer*, 2008, **49**, 1425-1434; (b) A. N. Semenov, J. F. Joanny, and A. R. Khokhlov, *Macromolecules*, 1995, **28**, 1066-1075.
15. J. Yang, X. Wang, G. Fuh, L. Yu, E. Wakshull, M. Khosraviani, E. S. Day, B. Demeule, J. Liu, S. J. Shire, N. Ferrara, and S. Yadav, *Mol. Pharm.*, 2014, **11**, 3421-3430.
16. G. Vauquelin and S. J. Charlton, *Br. J. Pharmacol.*, 2010, **161**, 488-508.
17. (a) W. Paul, ed. *Fundamental immunology*. 2012, Lippincott Williams and Wilkins. . 140-142; (b) L. J. Harris, S. B. Larson, E. Skaletsky, and A. Mcpherson, *Immunol. Rev.*, 1998, **163**, 35-43; (c) X. Wang, S. Kumar, and S. Singh, *Pharm. Res.*, 2011, **28**, 3128-3143.
18. (a) J. Vlasak and R. Ionescu, *MAbs*, 2011, **3**, 253-263; (b) B. Yan, D. Boyd, T. Kaschak, J. Tsukuda, A. Shen, Y. Lin, S. Chung, P. Gupta, A. Kamath, A. Wong, J.-M. Vernes, G. Y. Meng, K. Totpal, G. Schaefer, G. Jiang, B. Nogal, C. Emery, M. Vanderlaan, P. Carter, R. Harris, and A. Amanullah, *J. Biol. Chem.*, 2012, **287**, 5891-5897.
19. Y. Wang, D. Fei, M. Vanderlaan, and A. Song, *Angiogenesis*, 2004, **7**, 335-345

